Iqbal J Hussain Sells $131K of Centessa Pharmaceuticals plc (CNTA) — SEC Form 4, Sep 15, 2025

Open-Market Net Sale · SEC Form 4

−$131,101

10b5-1 Plan (Partial)

Reporting Owner

Iqbal J Hussain

TXN 2025-09-15 · FILED 2025-09-15

Equity Position 117K sh 116,886 → 116,886

Filing Lag 0 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Centessa Pharmaceuticals plc

CNTA CIK 0001847903

Reporting Owner

Name	Relationship
Iqbal J Hussain CIK 0001862050	GC

Iqbal J Hussain at Centessa Pharmaceuticals plc Full insider history

Bought (12 mo) —

Sold (12 mo) $1,170,753

More from this insider at Centessa Pharmaceuticals plc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Ordinary SharesF1	2025-09-15	M - Exercise	6,000 A	$5.84	+$35,040	111,386	Direct
Ordinary SharesF1 F2 F3	2025-09-15	S - Sale 10b5-1	6,000 D	$21.85	-$131,101	105,386	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Share Option (right to buy)F4 F1	$5.84	2025-09-15	M - Exercise	6,000 D	$0.00	2031-02-19	6,000 Ordinary Shares	Direct

Non-Derivative Holdings

Title	Shares Held	Ownership
Ordinary SharesF1	5,500	Indirect By spouse

Footnotes (4)

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Show more
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024. Show more
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.74 to $21.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Show more
F4: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. Show more

5%+ Holders · 13D/G 2 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Centessa Pharmaceuticals plc

GET /v1/forms/4/0001470831-25-000200 API docs